Background Current treatment guidelines recommend adjuvant mitotane after resection of
adrenocortical carcinoma with high-risk features (eg, tumor rupture, positive margins,
positive lymph nodes, high grade, elevated mitotic index, and advanced stage). Limited data
exist on the outcomes associated with these practice guidelines. Study Design Patients who
underwent resection of adrenocortical carcinoma from 1993 to 2014 at the 13 academic
institutions of the US Adrenocortical Carcinoma Group were included. Factors associated …